Pfizer’s current research on a potential blockbuster anti-Alzheimer drug is currently back to drawing-board status. According to the pharma company

[T]he drug, called Dimebon, had shown virtually no effect after six months in treating the cognitive decline or behavioral problems associated with Alzheimer’s when compared with a placebo.

Apparently, Wall Street has been watching the results of this Phase I study; the verdict is still out on whether Pfizer will continue to fund the research for this agent — designed to work better and longer at inhibiting some of the most distressing symptoms related to the disease. | LINK

Related Posts Within Doctor Pundit:

1. Study: First Available Mega-Combination Cardiac Drug in Development Sometimes the fastest way from an NDA to market is...
2. Study: Anti-Inflammatory Painkillers Not Seen as Protective against Dementia Development Nothing, it seems, lends itself to the aphorism that if-one-doesn’t-like-the-results-of-some-medical-trial-just-wait-a-few-and-you’ll-be-rewarded...
3. Study: Authors Attempt to Characterize Dementia As a Terminal Illness In the upcoming NEJM, a large prospective study makes the...
4. Scientists Find New Avenue in Mechanism of Alzheimer Dementia Development The major focus of research into the biochemical causes and...
5. Study Highlights Possible ‘Nutritional’ Beverage for Dementia A nationwide clinical trial is underway to determine if a...